The work focuses on multiple myeloma, the most common cancer of the blood and lymphatic system. Bortezomib is the first proteasome inhibitor drug to revolutionize the treatment of multiple myeloma in the past 10 years. Despite the very good efficacy of this class of drugs against myeloma, sooner or later resistance develops in almost all patients treated. There is no effective therapy for this case, so that the majority of these patients die within a few years. Our vision is to make a significant contribution to the development of new forms of therapy against multiple melanoma.